Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.50 |
| ▸ | ITGAV | P06756 | 16/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.49 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.49 |
| ▸ | ITGA8 | P53708 | 2/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773288 | 0.94 | ITGB3 (0.52) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6772198 | 0.93 | GPR139 (0.53) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL14536297 | 0.91 | ITGB3 (0.44) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6778577 | 0.91 | ITGB3 (0.50) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6774640 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL242674 | 0.90 | ITGB3 (0.55) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6784179 | 0.90 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6778074 | 0.89 | GPR139 (0.47) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6779336 | 0.89 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6773834 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | claimed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | claimed |
| CN-119630399-A | Periostin-mediated disease and prophylactic or therapeutic agent for itching associated with the disease | 国立大学法人佐贺大学 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024024915-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PERIOSTIN-MEDIATED DISEASE AND PRURITUS ASSOCIATED THEREWITH | 国立大学法人佐賀大学 | 2024-02-01 | — | — | WO | disclosed |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100297025-A1 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives | GUERBET. | 2010-11-25 | — | — | US | disclosed |
| US-7780953-B2 | Compositions magnetic particles covered with gem-bisphosphonate derivatives | GUERBET (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-1227847-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND ALPHAVBETA3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-07 | — | — | EP | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001024827-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297025-A1 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives | PHOSPHO1, SGMS2, PTEN | ITGB3 1890/4885ITGAV 2433/4885ITGB6 2178/4885 |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB3 1/4885ITGAV 11/4885ITGB6 14/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB3 3/4885ITGAV 4/4885ITGB6 38/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGB6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.